Global Cold Sore Treatment For Hsv 1 Virus Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 927.29 Million |
 Taille du marché (année de prévision) |
USD 1,501.88 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial du traitement des boutons de fièvre (pour le virus HSV 1), par type de traitement (médicaments, produits appliqués, patchs contre les boutons de fièvre et autres (produits non médicamenteux)), voie d'administration (orale, topique et autres), mode d'achat (médicament en vente libre et sur ordonnance), type de souche (virus de l'herpès simplex de type 1 et virus de l'herpès simplex de type 2), type de médicament (générique et de marque), type de population (adultes, pédiatrie et gériatrie), sexe (femme et homme), utilisateur final (soins de santé à domicile, hôpitaux, cliniques spécialisées et autres), canal de distribution (appels d'offres directs, ventes au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2031.
Analyse du marché et de la taille du traitement des boutons de fièvre (pour le virus HSV 1)
Le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) devrait connaître une croissance du marché au cours de la période de prévision de 2024 à 2031.
Le marché mondial du traitement de l'herpès labial (pour le virus HSV 1) est stimulé par la forte prévalence des virus HSV-1 et H11, qui est l'un des principaux moteurs du marché mondial du traitement de l'herpès labial (pour le virus HSV 1). Le HSV-1 est très répandu, infectant environ 67 % de la population mondiale de moins de 50 ans. De même, les infections H11 sont courantes chez les volailles, avec une transmission occasionnelle à l'homme.
Cette prévalence accroît la demande de traitements efficaces. Les personnes atteintes du HSV-1 ou du H11 souffrent souvent de poussées d’herpès labial récurrentes, qui peuvent être douloureuses et inesthétiques. Cela crée une forte demande des consommateurs pour des traitements capables de soulager les symptômes, de réduire la fréquence des poussées et de prévenir la transmission. Les changements de mode de vie, notamment l’augmentation du stress, de la fatigue et de l’exposition au soleil, peuvent déclencher des poussées. La population vieillissante est également plus sensible aux boutons de fièvre, ce qui contribue à des taux d’infection plus élevés.
Data Bridge Market Research analyse que le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) croît avec un TCAC de 6,6 % au cours de la période de prévision de 2024 à 2031 et devrait atteindre 1 501,88 millions USD d'ici 2031 contre 927,29 millions USD en 2023.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (Personnalisable 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Type de traitement (médicaments, produits appliqués, patchs pour boutons de fièvre et autres (produits non médicamenteux)), voie d'administration (orale, topique et autres), mode d'achat ( médicament en vente libre et sur ordonnance ), type de souche (virus de l'herpès simplex de type 1 et virus de l'herpès simplex de type 2), type de médicament (générique et de marque), type de population (adultes, pédiatrie et gériatrie), sexe (femme et homme), utilisateur final ( soins de santé à domicile , hôpitaux, cliniques spécialisées et autres), canal de distribution (appels d'offres directs, ventes au détail et autres) |
|
Pays couverts |
États-Unis, Canada et Mexique, Royaume-Uni, Allemagne, France, Espagne, Italie, Belgique, Russie, Suisse, Pays-Bas, Turquie et reste de l'Europe, Chine, Australie, Japon, Inde, Singapour, Corée du Sud, Malaisie, Thaïlande, Indonésie, Philippines et reste de l'Asie-Pacifique, Brésil, Argentine et reste de l'Amérique du Sud, Afrique du Sud, Égypte, Arabie saoudite, Émirats arabes unis et reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies et Devirex AG, entre autres |
Définition du marché
Le HSV-1, ou virus de l'herpès simplex de type 1, est un virus courant qui provoque des boutons de fièvre, également appelés boutons de fièvre, sur les lèvres et autour de la bouche. Ces boutons sont des cloques remplies de liquide qui peuvent être douloureuses et durer environ 7 à 10 jours.
Le traitement des boutons de fièvre implique généralement des médicaments antiviraux, tels que l'acyclovir, le famciclovir ou le valacyclovir, qui peuvent aider à réduire la gravité et la durée des poussées. Les crèmes et les onguents en vente libre, tels que ceux contenant du docosanol ou de l'alcool benzylique , peuvent également soulager les symptômes. Garder la zone affectée propre et éviter les déclencheurs, tels que le stress ou l'exposition au soleil, peut aider à prévenir les poussées.
Dynamique du marché mondial du traitement des boutons de fièvre (pour le virus HSV 1)
Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteurs
- Prévalence croissante des infections par boutons de fièvre
La prévalence croissante des infections par boutons de fièvre, due à l'évolution des modes de vie, au vieillissement de la population, à une sensibilisation accrue et à la mondialisation, est un facteur clé du marché mondial du traitement des boutons de fièvre (pour le virus HSV 1). Cette tendance devrait se poursuivre, conduisant à de nouvelles innovations et au développement de nouvelles options de traitement pour les personnes touchées par ces infections.
- Sensibilisation croissante aux symptômes de l'herpès labial et aux options de traitement
L’accessibilité accrue des informations sur les boutons de fièvre par le biais de divers canaux médiatiques, tels qu’Internet, les réseaux sociaux et les campagnes de santé, a permis de mieux faire connaître les signes et symptômes des boutons de fièvre. Cette sensibilisation accrue a conduit davantage de personnes à rechercher des conseils médicaux et un traitement pour leurs boutons de fièvre, ce qui a stimulé la croissance du marché.
Opportunité
- Progrès croissants dans le traitement des infections dues aux boutons de fièvre
Les avancées dans le traitement des infections par l'herpès labial (HSV-1) et le zona (virus varicelle-zona) ont conduit au développement de médicaments antiviraux plus puissants et moins d'effets secondaires. Des systèmes d'administration de médicaments innovants, tels que les formulations liposomales, ont amélioré l'efficacité du traitement et l'observance du traitement par les patients.
Retenue/Défi
- Complexité croissante du développement des vaccins
Le développement d'un vaccin contre l'herpès labial causé par le virus HSV-1 se heurte à des obstacles considérables. L'un de ces défis est la capacité du virus à établir une latence dans les ganglions nerveux, ce qui le rend difficile à cibler avec des vaccins car il reste dormant dans des réservoirs viraux inactifs. De plus, les mécanismes d'évasion immunitaire du HSV-1 posent des difficultés pour induire une réponse immunitaire robuste et durable par la vaccination. Malgré ces défis, la poursuite de la recherche et de l'innovation est essentielle pour faire progresser le développement de vaccins et réduire le fardeau des infections par le HSV-1 dans le monde.
Développements récents
- En août 2019, Sun Pharmaceutical Industries Ltd. a annoncé que l'une de ses filiales avait concédé un accord de licence à une filiale de China Medical System Holding Ltd. pour développer et commercialiser 7 médicaments génériques en Chine. Cet accord aide l'entreprise à développer ses activités et à renforcer le profil du produit
- En novembre 2020, Amneal Pharmaceuticals LLC avait annoncé l'approbation par la FDA de sa demande abrégée de nouveau médicament (ANDA) pour la crème Acyclovir à 5 %. Il s'agit de la version générique de Zovirax pour le traitement de l'herpès labial chez les adolescents. L'initiative de l'entreprise entraînerait une augmentation de la distribution du produit, une augmentation de la notoriété de la marque et une augmentation des ventes. Cela se traduirait par une croissance positive du marché
- En août 2020, GSK a finalisé l'acquisition d'Affinivax, Inc. a annoncé avoir finalisé l'acquisition d'Affinivax, Inc. (Affinivax), une société biopharmaceutique en phase clinique basée à Cambridge, dans le Massachusetts. Les vaccins antipneumococciques de nouvelle génération sont les plus développés d'une nouvelle classe de vaccins qu'Affinivax dirige dans le développement de vaccins antipneumococciques de nouvelle génération
Portée du marché mondial du traitement des boutons de fièvre (pour le virus HSV 1)
Le marché mondial du traitement de l'herpès labial (pour le virus HSV 1) est segmenté en neuf segments notables en fonction du type de traitement, de la voie d'administration, du mode d'achat, du type de souche, du type de médicament, du type de population, du sexe, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences entre vos marchés cibles.
Type de traitement
- Médicaments
- Produits appliqués
- Patchs pour boutons de fièvre
- Autres (produits non médicamenteux)
Sur la base du type de traitement, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en médicaments, produits appliqués, patchs contre les boutons de fièvre et autres (produits non médicamenteux).
Voie d'administration
- Oral
- Topique
- Autres
Sur la base de la voie d’administration, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en voie orale, topique et autres.
Mode d'achat
- Sur le comptoir
- Médicament sur ordonnance
Sur la base du mode d’achat, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en médicaments en vente libre et sur ordonnance.
Type de souche
- Virus de l'herpès simplex de type 1
- Virus de l'herpès simplex de type 2
Sur la base du type de souche, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en virus de l'herpès simplex de type 1 et virus de l'herpès simplex de type 2.
Type de médicament
- Générique
- De marque
Sur la base du type de médicament, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en génériques et en marques.
Type de population
- Adultes
- Pédiatrie
- Gériatrie
Sur la base du type de population, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en adultes, pédiatrie et gériatrie.
Genre
- Femelle
- Mâle
Sur la base du sexe, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en femmes et hommes.
Utilisateur final
- Soins à domicile
- Hôpitaux
- Cliniques spécialisées
- Autres
Sur la base de l'utilisateur final, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en soins de santé à domicile, hôpitaux, cliniques spécialisées et autres.
Canal de distribution
- Appels d'offres directs
- Ventes au détail
- Autres
Sur la base du canal de distribution, le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est segmenté en appels d’offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché mondial du traitement des boutons de fièvre (pour le virus HSV 1)
Le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) est analysé et des informations et tendances sur la taille du marché sont fournies en fonction du type de traitement, de la voie d'administration, du mode d'achat, du type de souche, du type de médicament, du type de population, du sexe, de l'utilisateur final et du canal de distribution comme référencé ci-dessus.
Les pays couverts dans ce rapport sur le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) sont les États-Unis, le Canada et le Mexique, le Royaume-Uni, l'Allemagne, la France, l'Espagne, l'Italie, la Belgique, la Russie, la Suisse, les Pays-Bas, la Turquie et le reste de l'Europe, la Chine, l'Australie, le Japon, l'Inde, Singapour, la Corée du Sud, la Malaisie, la Thaïlande, l'Indonésie, les Philippines et le reste de l'Asie-Pacifique, le Brésil, l'Argentine et le reste de l'Amérique du Sud, l'Afrique du Sud, l'Égypte, l'Arabie saoudite, les Émirats arabes unis et le reste du Moyen-Orient et de l'Afrique.
L’Amérique du Nord devrait dominer le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) en raison de facteurs tels que la forte prévalence des boutons de fièvre, une infrastructure de soins de santé avancée, une forte sensibilisation des consommateurs et un pouvoir d’achat élevé, des initiatives de recherche et développement en cours, des réseaux de marketing et de distribution établis et une stigmatisation réduite entourant les comportements de recherche de traitement.
Les États-Unis devraient dominer le marché nord-américain du traitement des boutons de fièvre (pour le virus HSV 1) en raison de facteurs tels qu'une population importante, des dépenses de santé élevées, un système de santé sophistiqué, une industrie pharmaceutique étendue et une sensibilisation généralisée des consommateurs et un accès aux traitements des boutons de fièvre.
L'Allemagne devrait dominer le marché européen du traitement des boutons de fièvre (pour le virus HSV 1) en raison de son infrastructure de soins de santé avancée, de la demande importante des consommateurs pour les traitements des boutons de fièvre, de la force de l'industrie pharmaceutique, des efforts de recherche et développement considérables et des réseaux de distribution bien établis, ce qui en fait un pôle d'innovation et d'accessibilité dans la gestion des boutons de fièvre.
La Chine devrait dominer le marché du traitement des boutons de fièvre (pour le virus HSV 1) en Asie-Pacifique en raison de sa grande population, de l'augmentation des dépenses de santé, de l'expansion de l'industrie pharmaceutique, de la sensibilisation croissante des consommateurs et de la demande de traitements contre les boutons de fièvre, associés à une infrastructure de soins de santé en développement et à une prévalence croissante des boutons de fièvre.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché mondiales du traitement des boutons de fièvre (pour le virus HSV 1)
Le paysage concurrentiel du marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1).
Français Certains des principaux acteurs opérant sur le marché mondial du traitement des boutons de fièvre (pour le virus HSV 1) sont Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies et Devirex AG, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: REGULATIONS
5.1 REGULATION IN U.S.:
5.2 REGULATION IN CANADA:
5.3 REGULATION IN SPAIN:
5.4 REGULATION IN U.K.:
5.5 REGULATION IN INDIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION
6.1.2 GROWING AWARENESS ABOUT COLD SORE SYMPTOMS AND TREATMENT OPTIONS
6.1.3 IMPACT OF GENERIC DRUGS ON THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET
6.2 RESTRAINTS
6.2.1 DEVELOPMENT OF DRUG-RESISTANT STRAINS OF HSV-1 AND H11 VIRUSES
6.2.2 LACK OF CURATIVE TREATMENT FOR INFECTION
6.3 OPPORTUNITIES
6.3.1 RISING ADVANCEMENTS IN TREATMENTS FOR COLD SORE INFECTIONS
6.3.2 INCREASING ADOPTION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 INCREASING COMPLEXITY OF VACCINE DEVELOPMENT
6.4.2 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS IN TREATING COLD SORE
7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 MEDICATIONS
7.2.1 ANTIVIRAL AGENTS
7.2.2 ANALGESIC AGENTS
7.2.3 OTHERS
7.3 APPLIED PRODUCTS
7.3.1 BRANDED
7.3.2 GENERICS
7.4 COLD SORE PATCHES
7.4.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH
7.4.2 FILM FORMING PATCH
7.5 OTHERS (NON MEDICATED PRODUCTS)
8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.2.1 TABLETS
8.2.2 CAPSULES
8.2.3 OTHERS
8.3 TOPICAL
8.3.1 CREAM
8.3.2 LIP BALM
8.3.3 OTHERS
8.4 OTHERS
9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION DRUG
10 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE
10.1 OVERVIEW
10.2 HERPES SIMPLEX TYPE 1 VIRUS
10.3 HERPES SIMPLEX TYPE 2 VIRUS
11 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERIC
11.3 BRANDED
12 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULTS
12.3 PEDIATRICS
12.4 GERIATRICS
13 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER
13.1 OVERVIEW
13.2 FEMALE
13.3 MALE
14 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER
14.1 OVERVIEW
14.2 HOME HEALTHCARE
14.3 HOSPITALS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K.
16.3.4 ITALY
16.3.5 SPAIN
16.3.6 RUSSIA
16.3.7 SWITZERLAND
16.3.8 NETHERLAND
16.3.9 TURKEY
16.3.10 BELGIUM
16.3.11 REST OF EUROPE
16.4 ASIA-PACIFIC
16.4.1 CHINA
16.4.2 JAPAN
16.4.3 INDIA
16.4.4 AUSTRALIA
16.4.5 SOUTH KOREA
16.4.6 SINGAPORE
16.4.7 MALAYSIA
16.4.8 PHILIPPINES
16.4.9 INDONESIA
16.4.10 THAILAND
16.4.11 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 EGYPT
16.6.3 SAUDI ARABIA
16.6.4 U.A.E.
17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 FRESENIUS SE & CO. KGAA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 ZYDUS PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 COMPANY SHARE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 NOVARTIS AG
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 SUN PHARMACEUTICALS INDUSTRIES LIMITED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 AMNEAL PHARMACEUTICALS LLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 AMPARO MEDICAL TECHNOLOGIES
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 APOTEX INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BLISTEX INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CARMA LABS INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 CHURCH & DWIGHT CO., INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 DEVIREX AG
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FOCUS CONSUMER HEALTHCARE
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 GSK PLC.
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 HALEON GROUP OF COMPANIES
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 HETERO HEALTH CARE LIMITED
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 HIKMA PHARMACEUTICALS PLC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 QUANTUM HEALTH
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 URGO MEDICAL
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 VIATRIS INC.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 TREATMENT OF PEDIATRIC HSV INFECTIONS
TABLE 2 TREATMENT OPTIONS
TABLE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL OTHERS (NON MEDICATED PRODUCTS) IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL OVER THE COUNTER IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL PRESCRIPTION IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE, 2022- 2031 (USD THOUSAND)
TABLE 25 GLOBAL HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 26 GLOBAL HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 27 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE, 2022- 2031 (USD THOUSAND)
TABLE 28 GLOBAL GENERIC IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 29 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 30 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031
TABLE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE, 2022- 2031 (USD THOUSAND)
TABLE 32 GLOBAL ADULTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 33 GLOBAL PEDIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 34 GLOBAL GERIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER, 2022- 2031 (USD THOUSAND)
TABLE 36 GLOBAL FEMALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 37 GLOBAL MALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER, 2022- 2031 (USD THOUSAND)
TABLE 39 GLOBAL HOME HEALTHCARE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 40 GLOBAL HOSPITALS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 41 GLOBAL SPECIALTY CLINICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 42 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022- 2031 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 45 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 46 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031
TABLE 47 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 48 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 62 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 67 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 69 NORTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 77 U.S. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 79 U.S. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 80 U.S. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 82 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 87 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 CANADA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 CANADA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 CANADA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 95 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 97 CANADA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 99 CANADA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 100 CANADA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 101 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 102 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 107 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 109 CANADA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 MEXICO MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 MEXICO ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 MEXICO ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 114 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 117 MEXICO COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 119 MEXICO ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 120 MEXICO TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 121 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 122 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 126 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 127 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 128 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 129 MEXICO RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 131 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 EUROPE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 EUROPE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 EUROPE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 136 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 138 EUROPE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 140 EUROPE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 141 EUROPE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 142 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 143 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 148 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 149 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 150 EUROPE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 GERMANY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 GERMANY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 GERMANY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 156 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 158 GERMANY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 160 GERMANY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 161 GERMANY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 162 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 163 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 168 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 169 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 170 GERMANY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 FRANCE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 FRANCE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 FRANCE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 178 FRANCE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 184 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 187 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 188 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 189 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 190 FRANCE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 U.K. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 U.K. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 U.K. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 198 U.K. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 200 U.K. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 201 U.K. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 202 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 203 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 204 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 208 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 209 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 210 U.K. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 ITALY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 ITALY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 ITALY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 218 ITALY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 220 ITALY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 221 ITALY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 222 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 223 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 224 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 227 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 228 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 229 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 230 ITALY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 231 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 SPAIN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 SPAIN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 234 SPAIN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 235 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 238 SPAIN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 240 SPAIN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 241 SPAIN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 242 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 243 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 248 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 249 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 250 SPAIN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 251 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 RUSSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 RUSSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 254 RUSSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 258 RUSSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 260 RUSSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 261 RUSSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 262 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 263 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 265 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 266 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 268 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 269 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 270 RUSSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 272 SWITZERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 SWITZERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 SWITZERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 276 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 278 SWITZERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 280 SWITZERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 281 SWITZERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 282 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 283 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 284 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 285 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 288 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 289 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 290 SWITZERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 291 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 NETHERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 NETHERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 294 NETHERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 296 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 298 NETHERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 299 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 300 NETHERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 301 NETHERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 302 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 303 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 304 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 305 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 308 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 309 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 310 NETHERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 311 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 TURKEY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 TURKEY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 TURKEY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 316 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 317 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 318 TURKEY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 320 TURKEY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 321 TURKEY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 322 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 323 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 325 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 326 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 328 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 329 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 330 TURKEY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 331 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 BELGIUM MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 BELGIUM ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 BELGIUM ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 336 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 337 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 338 BELGIUM COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 340 BELGIUM ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 341 BELGIUM TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 342 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 343 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 344 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 346 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 347 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 348 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 349 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 350 BELGIUM RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 351 REST OF EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 353 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 354 ASIA-PACIFIC MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 358 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 360 ASIA-PACIFIC COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 362 ASIA-PACIFIC ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 363 ASIA-PACIFIC TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 364 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 365 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 366 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 367 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 368 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 370 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 371 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 372 ASIA-PACIFIC RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 374 CHINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 CHINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 376 CHINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 378 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 380 CHINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 381 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 382 CHINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 383 CHINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 384 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 385 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 386 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 387 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 388 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 389 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 390 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 391 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 392 CHINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 393 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 394 JAPAN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 395 JAPAN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 396 JAPAN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 397 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 398 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 399 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 400 JAPAN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 401 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 402 JAPAN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 403 JAPAN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 404 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 405 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 406 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 408 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 409 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 410 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 411 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 412 JAPAN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 413 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 414 INDIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 415 INDIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 416 INDIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 417 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 418 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 419 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 420 INDIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 421 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 422 INDIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 423 INDIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 424 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 425 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 426 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 427 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 428 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 429 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 430 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 431 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 432 INDIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 433 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 434 AUSTRALIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 435 AUSTRALIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 436 AUSTRALIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 437 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 438 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 440 AUSTRALIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 441 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 442 AUSTRALIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 443 AUSTRALIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 444 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 445 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 446 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 447 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 448 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 449 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 450 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 451 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 452 AUSTRALIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 453 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 454 SOUTH KOREA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 455 SOUTH KOREA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 456 SOUTH KOREA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 457 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 458 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 459 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 460 SOUTH KOREA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 461 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 462 SOUTH KOREA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 463 SOUTH KOREA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 464 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 465 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 466 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 467 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 468 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 469 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 470 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 471 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 472 SOUTH KOREA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 473 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 474 SINGAPORE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 475 SINGAPORE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 476 SINGAPORE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 477 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 479 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 480 SINGAPORE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 481 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 482 SINGAPORE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 483 SINGAPORE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 484 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 485 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 486 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 487 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 488 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 490 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 491 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 492 SINGAPORE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 493 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 494 MALAYSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 495 MALAYSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 496 MALAYSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 497 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 499 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 500 MALAYSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 501 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 502 MALAYSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 503 MALAYSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 504 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 505 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 506 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 507 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 508 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 509 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 510 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 511 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 512 MALAYSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 513 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 514 PHILIPPINES MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 515 PHILIPPINES ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 516 PHILIPPINES ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 517 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 518 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 519 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 520 PHILIPPINES COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 521 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 522 PHILIPPINES ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 523 PHILIPPINES TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 524 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 525 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 526 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 527 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 528 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 529 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 530 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 531 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 532 PHILIPPINES RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 533 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 534 INDONESIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 535 INDONESIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 536 INDONESIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 537 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 538 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 539 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 540 INDONESIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 541 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 542 INDONESIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 543 INDONESIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 544 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 545 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 546 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 548 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 549 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 550 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 551 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 552 INDONESIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 553 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 554 THAILAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 THAILAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 556 THAILAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 557 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 558 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 559 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 560 THAILAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 561 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 562 THAILAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 563 THAILAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 564 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 565 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 566 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 567 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 568 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 569 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 570 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 571 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 572 THAILAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 573 REST OF ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 574 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 575 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 576 SOUTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 577 SOUTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 578 SOUTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 579 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 580 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 581 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 582 SOUTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 583 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 584 SOUTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 585 SOUTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 586 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 587 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 588 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 589 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 590 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 591 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 592 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 593 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 594 SOUTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 595 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 596 BRAZIL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 597 BRAZIL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 598 BRAZIL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 599 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 600 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 601 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 602 BRAZIL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 603 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 604 BRAZIL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 605 BRAZIL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 606 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 607 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 608 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 609 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 610 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 611 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 612 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 613 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 614 BRAZIL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 615 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 616 ARGENTINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 617 ARGENTINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 618 ARGENTINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 619 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 620 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 621 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 622 ARGENTINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 623 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 624 ARGENTINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 625 ARGENTINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 626 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 627 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 628 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 629 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 630 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 631 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 632 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 633 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 634 ARGENTINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 635 REST OF SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 636 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 637 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 638 MIDDLE EAST AND AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 640 MIDDLE EAST AND AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 641 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 642 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 643 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 644 MIDDLE EAST AND AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 645 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 646 MIDDLE EAST AND AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 647 MIDDLE EAST AND AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 648 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 649 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 650 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 651 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 652 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 654 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 655 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 656 MIDDLE EAST AND AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 657 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 658 SOUTH AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 SOUTH AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 660 SOUTH AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 661 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 662 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 663 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 664 SOUTH AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 665 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 666 SOUTH AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 667 SOUTH AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 668 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 669 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 670 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 671 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 672 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 673 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 674 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 675 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 676 SOUTH AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 677 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 678 EGYPT MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 679 EGYPT ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 680 EGYPT ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 681 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 682 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 683 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 684 EGYPT COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 685 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 686 EGYPT ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 687 EGYPT TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 688 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 689 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 690 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 691 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 692 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 693 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 694 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 695 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 696 EGYPT RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 697 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 698 SAUDI ARABIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 699 SAUDI ARABIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 700 SAUDI ARABIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 701 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 702 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 703 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 704 SAUDI ARABIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 705 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 706 SAUDI ARABIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 707 SAUDI ARABIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 708 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 709 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 710 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 711 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 712 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 713 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 714 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 715 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 716 SAUDI ARABIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 717 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 718 U.A.E. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 719 U.A.E. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 720 U.A.E. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 721 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 722 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 723 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 724 U.A.E. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 725 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 726 U.A.E. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 727 U.A.E. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 728 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 729 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 730 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 731 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 732 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 733 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 734 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 735 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 736 U.A.E. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION
FIGURE 2 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION
FIGURE 11 GROWING PREVALENCE OF COLD SORE INFECTION IS DRIVING THE GROWTH OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET
FIGURE 16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2023
FIGURE 17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2023
FIGURE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 23 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 24 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2023
FIGURE 25 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 27 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 28 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2023
FIGURE 29 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, CAGR (2024-2031)
FIGURE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, LIFELINE CURVE
FIGURE 32 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2023
FIGURE 33 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 36 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2023
FIGURE 37 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 39 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2023
FIGURE 41 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 42 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, LIFELINE CURVE
FIGURE 44 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2023
FIGURE 45 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 46 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 47 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 48 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 49 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 50 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 51 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 52 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SNAPSHOT (2023)
FIGURE 53 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
FIGURE 54 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
FIGURE 55 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
FIGURE 56 AISA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
